Wyeth

Pfizer - Premarin/Prempro: 8th Circuit Affirms Arkansas Court Ruling in Products Liability Case

PharmaGossip (Free subscription) | 11/05/2009

The U.S. Court of Appeals for the 8th Circuit has upheld Arkansas district court decisions in a products liability case against pharmaceutical companies that are the makers of hormone therapy drugs that, combined, have been linked to breast cancer. In Donna Scroggin, v. Wyeth, and its divisions; Pharmacia & Upjohn Company L.L.C., (Case Nos: 08-2555, 08-2711 and 08-2713) on appeal from the United...

Research and Markets: Wyeth: Performance, Capabilities, Goals and Strategies in the Worldwide Pharmaceutical Market

Business Wire (Free subscription) | 10/30/2009

Merck/Schering Plough Merger Approved by The EU

Capital Observer (Free subscription) | 10/23/2009

Good Morning. The merger of Merck and Schering Plough has been approved by the EU and other approvals should be forthcoming in the weeks ahead. I have a position in Schering Plough and Merck but not nearly the size I had on the Pfizer/Wyeth combination. The reason being is that the spread on Pfizer/Wyeth was wider even though they had less overlap in their business. This was likely due to the larger...

Pharma’s Shift to Corporate Branding

Slice (Free subscription) | 10/22/2009

The traditional model for pharmaceutical public relations is to focus on the product brand, not the corporate brand. Healthcare consumers tend to identify more closely with product brand names rather than the company that controls that brand. Case in point: how many average consumers do you think realize that Wyeth makes Advil, that Johnson and Johnson [...]

TNF-Alpha Inhibitors Will Continue to Dominate First- and Second-Line Biologic Therapy for the Treatment of Rheumatoid Arthritis Through 2011

PR News Wire (Free subscription) | 10/22/2009

WALTHAM, Mass., Oct. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established branded drugs...

Animal health operation in Overland Park with 200 workers will close

kansascity.com (Free subscription) | 10/21/2009

Pfizer’s acquisition last week of Wyeth will result in the closing of an Overland Park facility, affecting 200 jobs. The operation served as the headquarters of Fort Dodge Animal Health, a former Wyeth subsidiary. Most of Fort Dodge Animal Health’s business and administrative functions in Overland Park will move to Pfizer Animal Health’s Madison, N.J., headquarters, the...

• Pfizer will shut down Fort Dodge Animal Health’s Overland Park operations - The Kansas City Business Journal

Pfizer Profit Jumps 26 Percent on Cost Cutting

ABC News (Free subscription) | 10/20/2009

Drugmaker Pfizer's 3Q profit jumps 26 percent on cost cuts; more expected with Wyeth deal done

Pfizer site cuts

PharmaGossip (Free subscription) | 10/20/2009

First details emerge of Pfizer site closures Tuesday , October 20, 2009 The completion of Pfizer's deal to acquire Wyeth has been followed swiftly by news that a number of manufacturing and research sites are to close. Pfizer had already said back in January when the $68 billion deal was announced that 19,000 employees were likely to lose their jobs, but this is the first time that specific information...

Pfizer marks shift to more diverse operation

Financial Times (Free subscription) | 10/19/2009

The world's largest pharmaceutical group moves away from a highly centralised group towards a more diverse and international operation as it celebrates the first day of its merger with Wyeth

Pfizer choosing sites to keep open

San Diego Union (Free subscription) | 10/17/2009

Pharmaceutical giant Pfizer said yesterday that it will take 30 to 60 days to determine which of the company's research sites to keep after this week's completion of its $68 billion acquisition of drug maker Wyeth.

Pfizer on track for speedy research alignment

Sify (Free subscription) | 10/17/2009

Megamergers in the pharmaceutical industry usually take many months to sort out, but the two research directors at newly combined Pfizer Inc. and Wyeth say they're off to a running start.

• Pfizer on track for speedy research alignment - Miami Herald
• Pfizer on track for speedy pruning, alignment of research programs post Wyeth acquisition - Star Tribune
• See the 4 articles on the same subject

Pfizer on track for speedy research alignment

Boston Globe (Free subscription) | 10/16/2009

Megamergers in the pharmaceutical industry usually take many months to sort out, but the two research directors at newly combined Pfizer Inc. and Wyeth say they're off to a running start.

Pfizer on track for speedy research alignment

San Fransisco Chronicle (Free subscription) | 10/16/2009

Megamergers in the pharmaceutical industry usually take many months to sort out, but the two research directors at newly combined Pfizer Inc. and Wyeth say they're off to a running start. They plan within just 30 days _ 60 days, tops _ to announce what... Sponsored Topics: Pfizer - Wyeth - Pharmaceutical industry - Business - Pharmaceutical

• Pfizer on track for speedy pruning, alignment of research programs post Wyeth acquisition - Star Tribune
• Pfizer on track for speedy research alignment - Seattle Times
• See the 5 articles on the same subject

Pfizer on track for speedy research alignment (AP via Yahoo! News)

WorkAtHome (Free subscription) | 10/16/2009

Megamergers in the pharmaceutical industry usually take many months to sort out, but the two research directors at newly combined Pfizer Inc. and Wyeth say they’re off to a running start.

Drug stocks retreat; Pfizer advances on merger

Market Watch (Free subscription) | 10/16/2009

BOSTON (MarketWatch) -- Drug stocks retreated early Friday while shares of Pfizer Inc. advanced on news that it has finally closed on its $68 billion merger with rival Wyeth. The NYSE Arca Pharmaceutical Index dipped 0.8% to 295.64 and the NYSE Arca Biotechnology Index slipped 0.5% to 926.26. Shares of Pfizer were up 1% at $17.79 as Wyeth shares ceased trading. Market Pulse Stories are Rapid-fire,...